Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Long-Term Investments (2017 - 2025)

Historic Long-Term Investments for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $10.0 million.

  • Arcus Biosciences' Long-Term Investments rose 40000.0% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 40000.0%. This contributed to the annual value of $14.0 million for FY2024, which is 8691.59% down from last year.
  • Per Arcus Biosciences' latest filing, its Long-Term Investments stood at $10.0 million for Q3 2025, which was up 40000.0% from $16.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Long-Term Investments registered a high of $218.7 million during Q3 2021, and its lowest value of $2.0 million during Q3 2024.
  • Moreover, its 5-year median value for Long-Term Investments was $90.0 million (2023), whereas its average is $87.4 million.
  • In the last 5 years, Arcus Biosciences' Long-Term Investments skyrocketed by 800111.11% in 2021 and then tumbled by 9867.55% in 2024.
  • Arcus Biosciences' Long-Term Investments (Quarter) stood at $182.0 million in 2021, then fell by 29.12% to $129.0 million in 2022, then fell by 17.05% to $107.0 million in 2023, then tumbled by 86.92% to $14.0 million in 2024, then dropped by 28.57% to $10.0 million in 2025.
  • Its last three reported values are $10.0 million in Q3 2025, $16.0 million for Q2 2025, and $8.0 million during Q1 2025.